For the GBM therapy, studies such as those conducted by Colombo et al. (2005) [276] and Qiao et al. (2018) [277] evaluated the combination of IL-2 with other therapeutic strategies, but mainly focusing on the effect promoted on T cells. Here, IL2 is linked to glioblastoma.